The pace of 2023 is about to enter, so looking back at the upcoming 2022, what major events have occurred in the pharmaceutical industry?
The seventh batch of national drug centralized procurement, the average price of selected drugs was reduced by 48%
On July 12, under the organization and guidance of the National Health Insurance Administration and other relevant departments, all provinces across the country formed a procurement alliance to carry out the seventh batch of centralized procurement
of state-organized drugs.
The results show that 6 products of 6 international pharmaceutical companies and 321 products of 211 domestic pharmaceutical companies are selected, and the average price of the selected drugs is reduced by 48%, which is expected to save 18.
5 billion yuan per year according to the agreed procurement volume.
The centralized procurement of drugs and consumables has played a relatively obvious role
in promoting the balanced state of medical insurance and medical fields, especially in improving the level of drug use, promoting the return of reasonable prices of drug consumables, and guiding the high-quality development of the pharmaceutical industry and medical institutions.
The normalization of centralized procurement has effectively ensured that patients can afford and use high-quality commonly used drugs, and stabilized the "basic plate"
of medical safety.
"Financial discounts" + "new medical infrastructure" should be carried out simultaneously to supplement the shortcomings of grassroots medical facilities
In September this year, the National Health Commission issued a notice that it intends to use financial discount loans to upgrade and transform medical equipment, and plans to issue supporting policies in the near future to further clarify the policy
of using financial discount loans to update and transform medical equipment in hospitals.
Specifically, in principle, the relevant financial discount loans are fully liberalized to all public and non-public medical institutions, and the loan amount of each hospital is not less than 20 million
.
The direction of loan use also includes the purchase
of various medical equipment such as diagnosis and treatment, clinical examination, severe disease, rehabilitation, and scientific research transformation.
In the market's view, the introduction of financial subsidized loans to support the renewal and transformation of medical equipment is also a key part
of the new domestic medical infrastructure.
On September 21, the Ministry of Finance issued the Notice on Issuing the 2022 Central Infrastructure Investment Budget in the Health Sector (Third Batch), which issued a central infrastructure investment budget of 26.
521 billion yuan for 2022, which will be used specifically for the health sector
.
In addition, the Outline of the Strategic Plan for Expanding Domestic Demand (2022-2035) also mentions that it is necessary to make up for the shortcomings in the construction of the medical field, improve the urban infectious disease treatment network, comprehensively improve the treatment capacity of county-level hospitals, continue to improve the facilities of county-level hospitals, and make up for the basic medical equipment of grassroots medical and health institutions such as township hospitals and village clinics
.
At present, many places have carried out project declaration, it is expected that from the second half of this year to next year, China's medical market will enter the peak period of medical equipment procurement, especially the procurement demand of the county medical market will continue to surge, and it is expected that nearly 200 billion yuan of incremental funds will enter the medical equipment procurement market
.
The "14th Five-Year Plan" for the development of the pharmaceutical industry was released
In January this year, the "14th Five-Year Plan" for the development of the pharmaceutical industry was issued, clarifying that by 2025, the main economic indicators will achieve medium-high growth, outstanding innovation achievements in frontier fields, enhanced innovation momentum, significantly improved the modernization level of the industrial chain, further improved the supply guarantee system of drugs and devices, and comprehensively improved
the level of internationalization.
By 2035, the strength of the pharmaceutical industry will achieve an overall leap; The innovation-driven development pattern has been fully formed, the industrial structure has been upgraded, the product range is more and the quality is better, so as to achieve a higher level to meet the health needs of the people and provide a solid guarantee
for the comprehensive construction of a healthy China.
According to the "14th Five-Year Plan" for the development of the pharmaceutical industry, innovation is still the main theme, and for the field of cutting-edge technology, it is clear that "support enterprises to base themselves on local resources and advantages, face the global market, focus on new targets and new mechanism drugs to carry out R&D layout, and actively lead innovation"
.
The goal of internationalization is also clearer, stating that "the export value of pharmaceuticals will continue to grow; Proprietary Chinese medicines have made breakthroughs in 'going global'; cultivated a number of world-renowned brands; and formed a group of large pharmaceutical companies with a global layout of R&D and production and a high proportion of international sales"
.
The Measures for the Supervision and Administration of Online Sales of Drugs came into force
On December 1, the Measures for the Supervision and Administration of Online Sales of Drugs (hereinafter referred to as the Measures) formulated by the State Administration for Market Regulation and the State Drug Administration were officially implemented
.
The Measures clearly stipulate that those engaged in online sales of drugs shall be drug marketing authorization holders or pharmaceutical trading enterprises
that have the ability to ensure the safety of drugs sold online.
That is, only drug marketing authorization holders or operating enterprises that have obtained drug business licenses can carry out drug online sales business
.
In addition, the Measures also specify that the real-name system is implemented for the online sales of prescription drugs, and prescription review and allocation are carried out in accordance with regulations; It is stipulated that prescription drugs and over-the-counter drugs shall be displayed separately, and it is clear that packaging, labels and other information shall not be directly displayed on the main page and homepage of prescription drug sales; Before passing the prescription review, information such as instructions must not be displayed, and services related to the purchase of prescription drugs must not be provided, which is intended to emphasize the management requirements
of "prescription before medicine" and prescription review.
With the formal implementation of the Measures for the Supervision and Administration of Online Drug Sales, online drug sales have entered a period
of standardization and strict supervision.
Dental implant collection landing
On August 18, the National Health Insurance Administration issued the Notice on Carrying out Special Governance of Oral Implant Medical Service Charges and Consumables Prices (Draft for Comments), which mentioned the establishment of an interprovincial procurement alliance
for dental implant consumables.
The Sichuan Provincial Medical Security Bureau led the establishment of an inter-provincial procurement alliance for dental implant consumables, in which all provinces should participate, which is actually equivalent to national procurement
.
This news is also regarded by the industry as a signal
that the collection of dental implants has officially landed.
It is reported that it also requires that in principle, the number of medical institutions (including private enterprises) participating in this collective procurement in each coordination area should account for more than 40% of the medical institutions carrying out dental implant services, or the total demand reported by the region should account for more than
50% of the total actual use in the previous year.
Where doctors of public medical institutions practice at multiple sites in private medical institutions and serve as responsible persons or business backbones, the public medical institutions shall urge them to standardize their participation in collective procurement
.
Medical institutions need to reply in writing to participate or not participate in this collection, and those who do not participate should explain the reasons
.
Each province separately organized public and private medical institutions in the province to participate in this collective procurement to fill in the procurement needs
of dental implant consumables.
Implement differentiated price policies
for public medical institutions that provide dental implant services but refuse to report or the reporting rate is less than 80% of the actual usage in the previous year.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
